Inbal MazorBadichi - Surgical Science Executive Marketing
| 0AAU Stock | 147.50 0.70 0.47% |
Executive
Inbal MazorBadichi is Executive Marketing of Surgical Science Sweden
| Age | 55 |
| Address | Drakegatan 7 A, Gothenburg, Sweden, 412 50 |
| Phone | 46 3 17 41 65 60 |
| Web | https://www.surgicalscience.com |
Surgical Science Management Efficiency
The company has return on total asset (ROA) of 0.0195 % which means that it generated a profit of $0.0195 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0436 %, meaning that it generated $0.0436 on every $100 dollars invested by stockholders. Surgical Science's management efficiency ratios could be used to measure how well Surgical Science manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Surgical Science's Net Tangible Assets are comparatively stable compared to the past year. Total Current Assets is likely to gain to about 997.8 M in 2024, whereas Other Assets are likely to drop slightly above 19.3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Bjarne Reinert | Leroy Seafood Group | 42 | |
| Alessandro DAniello | Datalogic | N/A | |
| Erik Holvik | Grieg Seafood | 46 | |
| Knut Utheim | Grieg Seafood | 58 | |
| Megan Blaylock | Science in Sport | N/A | |
| Aina Valland | Leroy Seafood Group | N/A | |
| Stephen Brobst | Teradata Corp | N/A | |
| Ivar Wulff | Leroy Seafood Group | 50 | |
| Andy Bott | Science in Sport | N/A | |
| Louis Landry | Teradata Corp | N/A | |
| Tor Homme | Grieg Seafood | N/A | |
| Michael Hutchinson | Teradata Corp | 58 | |
| Julia Brown | Universal Display Corp | 63 | |
| SangKyun Kim | Samsung Electronics Co | N/A | |
| Hans Ljen | Leroy Seafood Group | N/A | |
| Alexander Knudsen | Grieg Seafood | 50 | |
| Kathleen Mathisen | Grieg Seafood | 53 | |
| Grant Cumming | Grieg Seafood | 53 | |
| Andreas Kvame | Grieg Seafood | 62 | |
| Brian Millard | Universal Display Corp | 41 | |
| Hillary Ashton | Teradata Corp | 52 | |
Management Performance
| Return On Equity | 0.0436 | |||
| Return On Asset | 0.0195 |
Surgical Science Sweden Leadership Team
Elected by the shareholders, the Surgical Science's board of directors comprises two types of representatives: Surgical Science inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Surgical. The board's role is to monitor Surgical Science's management team and ensure that shareholders' interests are well served. Surgical Science's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Surgical Science's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Inbal MazorBadichi, Executive Marketing | ||
| Ran Bronstein, President Development | ||
| Anna Ahlberg, Chief Officer | ||
| Adv, Chief Officer | ||
| Tom Englund, Chief Officer | ||
| Daniel Evestedt, Head Development | ||
| Jeffrey Berkley, Chief Officer | ||
| Martin Jansson, Head Sales | ||
| Anders Larsson, CoFounder CTO | ||
| Gisli Hennermark, Advisor Director | ||
| Doron Zilberman, Executive Products |
Surgical Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Surgical Science a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0436 | |||
| Return On Asset | 0.0195 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 6.32 B | |||
| Shares Owned By Insiders | 25.73 % | |||
| Shares Owned By Institutions | 54.70 % | |||
| Revenue | 838.25 M | |||
| Gross Profit | 531.52 M | |||
| EBITDA | 179.07 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Surgical Stock Analysis
When running Surgical Science's price analysis, check to measure Surgical Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgical Science is operating at the current time. Most of Surgical Science's value examination focuses on studying past and present price action to predict the probability of Surgical Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgical Science's price. Additionally, you may evaluate how the addition of Surgical Science to your portfolios can decrease your overall portfolio volatility.